{"disease":{"id":"affective-disorder","name":"affective disorder"},"drugs":{"marketed":[{"drug_id":"cariprazine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vraylar","generic_name":"CARIPRAZINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"3267","mechanism":"Vraylar works by selectively blocking the D3 dopamine receptor, which helps regulate mood and behavior."},{"drug_id":"aripiprazole","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abilify","generic_name":"aripiprazole","company_name":"Generic (originally Otsuka/BMS)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Third-generation antipsychotic (D2 partial agonist)","quality_score":63,"revenue":"3000","mechanism":"Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it."},{"drug_id":"fluoxetine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prozac","generic_name":"fluoxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":81,"revenue":"1000.0","mechanism":"Fluoxetine inhibits CNS neuronal uptake of serotonin, though exact mechanism unknown."},{"drug_id":"olanzapine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"300","mechanism":null},{"drug_id":"olanzapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"300","mechanism":null},{"drug_id":"quetiapine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"quetiapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"sodium valproate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epilim","generic_name":"sodium valproate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"asenapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Saphris","generic_name":"ASENAPINE","company_name":"Hisamitsu","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2C","drug_class":"Atypical Antipsychotic [EPC]","quality_score":67,"revenue":null,"mechanism":"Saphris works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2C."},{"drug_id":"clozapine","indication_name":"Suicidal Behavior in Schizoaffective Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Clozaril","generic_name":"CLOZAPINE","company_name":"Jazz Pharmaceuticals","drug_phase":"marketed","molecular_target":"D2, 5-HT2A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":69,"revenue":null,"mechanism":"Clozapine's efficacy in schizophrenia may be due to its antagonism of D2 and 5-HT2A receptors."},{"drug_id":"bupropion-sr-150mg-bid","indication_name":"Prevention of Seasonal Affective Disorder (SAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bupropion SR 150mg bid","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Dopamine transporter (DAT), Norepinephrine transporter (NET)","drug_class":"Atypical antidepressant, Norepinephrine-dopamine reuptake inhibitor (NDRI)","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"clozaril","indication_name":"Suicidal Behavior in Schizoaffective Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clozaril","company_name":"Dong Wha Pharmaceutical Co. Ltd.","drug_phase":"phase_1","molecular_target":"Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E","drug_class":"","quality_score":12,"revenue":null,"mechanism":""},{"drug_id":"bupropion-immediate-release-ir","indication_name":"Seasonal Affective Disorder (SAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bupropion immediate release (IR)","generic_name":"bupropion-immediate-release-ir","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Dopamine transporter, Norepinephrine transporter","drug_class":"Norepinephrine-dopamine reuptake inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"carbamazepine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"risperidone","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Risperdal","generic_name":"risperidone","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder."},{"drug_id":"ziprasidone","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geodon","generic_name":"ziprasidone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical antipsychotic (second-generation)","quality_score":10,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class."},{"drug_id":"carbamazepin","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbamazepin","company_name":"Enanta Pharmaceuticals, Inc","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"valproic-acid","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depakene","generic_name":"valproic acid","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Broad-spectrum anticonvulsant that enhances GABA activity, blocks sodium and calcium channels, and inhibits histone deacetylase."},{"drug_id":"prozac","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prozac","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"lithium","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithobid","generic_name":"lithium carbonate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3","drug_class":"Mood stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"bupropion","indication_name":"Seasonal affective disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wellbutrin","generic_name":"bupropion","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor","drug_class":"NDRI (Norepinephrine-dopamine reuptake inhibitor)","quality_score":55,"revenue":null,"mechanism":"Norepinephrine-dopamine reuptake inhibitor (NDRI) that treats depression and aids smoking cessation without serotonergic side effects."},{"drug_id":"lithium-carbonate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Carbonate","generic_name":"LITHIUM CARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium carbonate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lurasidone","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Latuda","generic_name":"LURASIDONE","company_name":"Sunovion Pharms Inc","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Atypical Antipsychotic","quality_score":80,"revenue":null,"mechanism":"Latuda works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2A, which helps to regulate mood and reduce symptoms of psychosis."},{"drug_id":"doxepin","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zonalon","generic_name":"DOXEPIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":80,"revenue":null,"mechanism":"Zonalon works by blocking histamine H1 receptors in the brain, which helps to reduce anxiety and itching, and improve mood."},{"drug_id":"seroquel","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"seroquel","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"risperdal","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risperdal","company_name":"Ohio State University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"wellbutrin","indication_name":"Seasonal affective disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Wellbutrin","company_name":"Mclean Hospital","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"divalproex","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Divalproex","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fazaclo","indication_name":"Suicidal Behavior in Schizoaffective Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fazaclo","company_name":"Manhattan Psychiatric Center","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl894","indication_name":"Prevention of Seasonal Affective Disorder (SAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BUPROPION","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"elontril","indication_name":"Seasonal affective disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Elontril","company_name":"Boehringer Ingelheim","drug_phase":"phase_3","molecular_target":"Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"paliperidone","indication_name":"Schizoaffective Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PALIPERIDONE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Atypical Antipsychotic [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"abilify","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abilify","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"chlorpromazine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thorazine","generic_name":"chlorpromazine","company_name":"Generic (originally Rhône-Poulenc/Sanofi)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Sphingomyelin phosphodiesterase, 5-hydroxytryptamine receptor 1E","drug_class":"Typical antipsychotic (first-generation, phenothiazine)","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"lithium-citrate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Citrate","generic_name":"LITHIUM CITRATE","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium","quality_score":10,"revenue":null,"mechanism":"Lithium Citrate works by inhibiting glycogen synthase kinase-3, a key enzyme involved in the regulation of various cellular processes."}],"pipeline":[],"offLabel":[],"totalMarketed":40,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT07005245","title":"Survey on the Reproductive and Child-Rearing Situations of Patients With Severe Mental Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":77145,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT05480150","title":"Chinese Longitudinal and Systematic Study of Bioplar Disorder","phase":"NA","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT00001486","title":"Genetic Study of Schizophrenia","phase":"","overall_status":"COMPLETED","enrollment_count":4914,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT07129408","title":"Epidemiological Study on the Prevalence of Mental Disorders in Slovakia","phase":"","overall_status":"COMPLETED","enrollment_count":3100,"lead_sponsor_name":"Comenius University","has_results":false},{"nct_id":"NCT00001198","title":"Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia","phase":"","overall_status":"TERMINATED","enrollment_count":1556,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT00212784","title":"Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1225,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT06657430","title":"A Study on the Preference of Risperidone Dosage Forms","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT03335696","title":"Predicting MRI Abnormalities With Longitudinal Data of the Whitehall II Substudy","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04745507","title":"Implementation, Efficacy and Costs of Inpatient Equivalent Home-Treatment in German Mental Health Care","phase":"","overall_status":"UNKNOWN","enrollment_count":629,"lead_sponsor_name":"Vivantes Netzwerk für Gesundheit GmbH","has_results":false},{"nct_id":"NCT05127837","title":"CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Technologies","phase":"NA","overall_status":"COMPLETED","enrollment_count":601,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT03109028","title":"Mental Health in Refugees and Asylum Seekers","phase":"NA","overall_status":"COMPLETED","enrollment_count":584,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT07137572","title":"Arts-based Social Prescribing for Mental Health","phase":"NA","overall_status":"COMPLETED","enrollment_count":541,"lead_sponsor_name":"KAVADIA ELENI","has_results":false},{"nct_id":"NCT04580134","title":"CLOZAPINE Response in Biotype-1","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":524,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT05658510","title":"Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":452,"lead_sponsor_name":"BioXcel Therapeutics Inc","has_results":false},{"nct_id":"NCT04268303","title":"Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":380,"lead_sponsor_name":"BioXcel Therapeutics Inc","has_results":true},{"nct_id":"NCT06738953","title":"Prevention of Mental Disorders Through Self-efficacy Interventions","phase":"NA","overall_status":"RECRUITING","enrollment_count":378,"lead_sponsor_name":"Health and Medical University Potsdam","has_results":false},{"nct_id":"NCT03240380","title":"Joint Crisis Plans or Crisis Cards for People With Severe Mental Disorders to Reduce Coercion in Psychiatric Care.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":374,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT05030272","title":"Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings","phase":"NA","overall_status":"COMPLETED","enrollment_count":343,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT06594263","title":"Validation of the French Version of the Perinatal Assessment of Paternal Affectivity (PAPA)","phase":"","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT06831435","title":"Effectiveness of Digital Cognitive Behavioral Therapy for the Treatment of Depression: a Real-world Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":325,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06740383","title":"Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services","phase":"","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT04068467","title":"Evaluation of mHealth for Serious Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":315,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06033326","title":"Validation of the French Version of the Lithium Knowledge Test (LKT)","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT05934474","title":"Biocollection on Peripheral Inflammation","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04512066","title":"A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":287,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT00942981","title":"Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography","phase":"","overall_status":"COMPLETED","enrollment_count":283,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT05208190","title":"Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"New York State Psychiatric Institute","has_results":false},{"nct_id":"NCT05273164","title":"State Representation in Early Psychosis","phase":"","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT03559426","title":"Research Into Antipsychotic Discontinuation and Reduction Trial","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":253,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT03050853","title":"The Appeal and Impact of E-cigarettes in Smokers With SMI","phase":"NA","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Dartmouth-Hitchcock Medical Center","has_results":false},{"nct_id":"NCT04106960","title":"Quantitative Investigation of Environment and Participation","phase":"","overall_status":"UNKNOWN","enrollment_count":235,"lead_sponsor_name":"Queen Margaret University","has_results":false},{"nct_id":"NCT02675257","title":"Depression and Diabetes Control Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"Forschungsinstitut der Diabetes Akademie Mergentheim","has_results":false},{"nct_id":"NCT03848234","title":"Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":209,"lead_sponsor_name":"Tangent Data","has_results":false},{"nct_id":"NCT03829280","title":"Cognitive Adaption Training-Effectiveness in Real-world Settings and Mechanism of Action (CAT-EM)","phase":"NA","overall_status":"COMPLETED","enrollment_count":205,"lead_sponsor_name":"The University of Texas Health Science Center at San Antonio","has_results":false},{"nct_id":"NCT07098169","title":"Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy","phase":"NA","overall_status":"RECRUITING","enrollment_count":201,"lead_sponsor_name":"University of California, San Diego","has_results":false},{"nct_id":"NCT05877716","title":"EPI-MINN: Targeting Cognition and Motivation - National","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT03033420","title":"Reducing the Rate and Duration of Re-ADMISsions Among Patients With Unipolar Disorder and Bipolar Disorder Using Smartphone-based Monitoring and Treatment - The RADMIS Trials","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Psychiatric Centre Rigshospitalet","has_results":false},{"nct_id":"NCT04554121","title":"Efficacy of Personalizing Cognitive Remediation for Schizophrenia by Targeting Impairments in Early Auditory Processing","phase":"NA","overall_status":"COMPLETED","enrollment_count":194,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT05725785","title":"Technology-Assisted Implementation of a Mobile Health Program for Serious Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":191,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06758414","title":"CBT-CP for Veterans With SMI","phase":"NA","overall_status":"RECRUITING","enrollment_count":190,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT04298450","title":"ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention","phase":"NA","overall_status":"COMPLETED","enrollment_count":186,"lead_sponsor_name":"Centre for Addiction and Mental Health","has_results":false},{"nct_id":"NCT05824117","title":"Enhancing Educational and Vocational Recovery in Adolescents and Young Adults With Early Psychosis Through Supported Employment and Education.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":184,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT00057707","title":"Effects of Modafinil on Brain Function in Patients With Schizophrenia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT03049813","title":"Virtual Reality Job Interview Training in Severe Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"University of Michigan","has_results":true},{"nct_id":"NCT03390491","title":"OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Center for Social Innovation, Massachusetts","has_results":false},{"nct_id":"NCT04113993","title":"Bazedoxifene -Treatment for Women With Schizophrenia","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"The Alfred","has_results":false},{"nct_id":"NCT06423651","title":"Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders","phase":"NA","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Universitat Autonoma de Barcelona","has_results":false},{"nct_id":"NCT05538832","title":"Remote State Representation in Early Psychosis","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT02815813","title":"Lifestyle Intervention for Young Adults With Serious Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Dartmouth-Hitchcock Medical Center","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}